Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAY1161909 + Paclitaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY1161909 | BAY 1161909|Empesertib | MPS1 Inhibitor 27 | BAY1161909 (Empesertib), an inhibitor of TTK (MPS1), inhibits the spindle assembly checkpoint to induce cell death (PMID: 28539250, PMID: 32338514). | |
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02138812 | Phase I | BAY1161909 + Paclitaxel | Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel | Terminated | USA | 0 |